Corp /De/Bristol Myers Squi... Net Worth

The estimated Net Worth of Corp /De/Bristol Myers Squi... is at least $1.25 milliard dollars as of 9 July 2020. Corp Squi owns over 2,241 units of Acceleron Pharma Inc stock worth over $1,252,771,163 and over the last 4 years Corp sold XLRN stock worth over $229,209.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Corp Squi XLRN stock SEC Form 4 insiders trading

Corp has made over 2 trades of the Acceleron Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Corp sold 2,241 units of XLRN stock worth $229,209 on 9 July 2020.

The largest trade Corp's ever made was buying 108,108 units of Acceleron Pharma Inc stock on 1 July 2020 worth over $9,999,990. On average, Corp trades about 55,175 units every 4 days since 2020. As of 9 July 2020 Corp still owns at least 7,008,510 units of Acceleron Pharma Inc stock.

You can see the complete history of Corp Squi stock trades at the bottom of the page.

What's Corp Squi's mailing address?

Corp's mailing address filed with the SEC is 86 MORRIS AVENUE430 E. 29TH STREET, 14 FLOOR, SUMMITNEW YORK, NJNY, 0790110016.

Insiders trading at Acceleron Pharma Inc

Over the last 11 years, insiders at Acceleron Pharma Inc have traded over $211,038,855 worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth $172,392,007 . The most active insiders traders include Corp /De/ Celgene, Richard F Pops et Anthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of $7,646,210. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth $132,165.

What does Acceleron Pharma Inc do?

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Complete history of Corp Squi stock trades at Acceleron Pharma Inc

Acceleron Pharma Inc executives and stock owners

Acceleron Pharma Inc executives and other stock owners filed with the SEC include:

• Habib Dable,
  President, Chief Executive Officer, Director
• Kevin McLaughlin,
  Chief Financial Officer, Senior Vice President, Treasurer
• Sujay Kango,
  Executive Vice President and Chief Commercial Officer
• Ravindra Kumar,
  Senior Vice President, Chief Scientific Officer
• Francois Nader,
  Independent Chairman of the Board
• Joseph Zakrzewski,
  Independent Director
• Terrence Kearney,
  Independent Director
• Thomas McCourt,
  Independent Director
• Karen Smith,
  Independent Director
• Todd James,
  Senior Vice President Corporate Affairs and Investor Relations
• Kemal Malik,
  Independent Director
• Christopher Hite,
  Director
• Laura Hamill,
  Director
• Jay Backstrom,
  Executive Vice President - Research and Development
• Terrance Mcguire,
  Director
• Tom Maniatis,
  Director
• Jean George,
  Director
• John L Knopf,
  CEO and President
• Steven D Ertel,
  SVP & Chief Business Officer
• Matthew L Sherman,
  SVP & Chief Medical Officer
• Richard F Pops,
  Director
• Adam M Veness,
  SVP, General Counsel and Sec.
• John D Quisel,
  EVP, Chief Business Officer
• Christopher Rovaldi,
  SVP, Program Mgmt and Ops
• Robert K Zeldin,
  EVP & Chief Medical Officer
• Corp /De/ Celgene,
  10% owner
• Anthony B Evnin,
  Director
• Edwin M Jr Kania,
  Director
• Venture Management Co Iv Ll...,
  
• Venture Management Co Iv Ll...,
  
• Advisors Llcorbimed Capital...,
  
• Corp /De/Bristol Myers Squi...,